Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse 04:00:02 2024-03-27 pm EDT 5-day change 1st Jan Change
269.4 USD +1.48% Intraday chart for Charles River Laboratories International, Inc. +0.45% +13.95%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Deutsche Bank Raises Price Target on Charles River Laboratories to $300 From $275, Keeps Buy Rating MT
Charles River Laboratories International, Inc. Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine CI
Argus Raises Price Target on Charles River Laboratories International to $290 From $200, Maintains Buy Rating MT
Charles River Laboratories International, Navega Therapeutics Partner for Production of AAV-Based Gene Therapy MT
Charles River Laboratories International, Inc. and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration CI
Transcript : Charles River Laboratories International, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:15 AM
Charles River Laboratories International Insider Sold Shares Worth $959,545, According to a Recent SEC Filing MT
DURECT Corporation and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for Alzet® Product Line in U.S. and Canada CI
Charles River Laboratories International Insider Sold Shares Worth $1,268,500, According to a Recent SEC Filing MT
Charles River Laboratories International, Wheeler Bio Collaborate on Portable CMC Platform MT
Transcript : Charles River Laboratories International, Inc. - Special Call
Charles River Laboratories International Sets Accord With Wheeler Bio on Clinical Trials MT
Charles River Laboratories International, Inc. Announces Strategic Agreement with Wheeler Bio, Inc CI
Deutsche Bank Raises Charles River Laboratories International Price Target to $275 From $245, Maintains Buy Rating MT
Morgan Stanley Raises Price Target on Charles River Laboratories International to $235 From $205, Keeps Equalweight Rating MT
TD Cowen Adjusts Charles River Laboratories International's PT to $260 From $193, Keeps Market Perform Rating MT
Stephens Adjusts Charles River Laboratories International's PT to $280 From $270, Keeps Overweight Rating MT
Citigroup Adjusts Price Target on Charles River Laboratories International to $250 From $215, Maintains Neutral Rating MT
UBS Adjusts Charles River Laboratories International Price Target to $290 From $270, Maintains Buy Rating MT
JPMorgan Adjusts Price Target on Charles River Laboratories International to $280 From $270, Maintains Overweight Rating MT
Baird Adjusts Price Target on Charles River Laboratories International to $268 From $252, Maintains Outperform Rating MT
Guggenheim Downgrades Charles River Laboratories International to Neutral From Buy MT
Transcript : Charles River Laboratories International, Inc., Q4 2023 Earnings Call, Feb 14, 2024
Charles River Laboratories Q4 Non-GAAP Earnings, Revenue Fall MT
(CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Forecasts Fiscal Year 2024 EPS Range $10.90 - $11.40 MT
Chart Charles River Laboratories International, Inc.
More charts
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (63.4%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (19.2%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (17.5%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (83.3%) and sales of products (16.7%). Net sales are distributed geographically as follows: the United States (56.8%), Europe (26%), Canada (11.8%), Asia/Pacific (4.9%) and other (0.4%).
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
269.4 USD
Average target price
262.1 USD
Spread / Average Target
-2.69%
Consensus
  1. Stock
  2. Equities
  3. Stock Charles River Laboratories International, Inc. - Nyse
  4. News Charles River Laboratories International, Inc.
  5. Charles River Laboratories to Work With Ziphius Vaccines to Manufacture Starting Materials for Clinical-Stage Research